Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by scarlet1967on Feb 06, 2024 7:37pm
176 Views
Post# 35866508

CQDM

CQDM
Chemotherapy used to treat colorectal cancer is associated with serious side effects that often lead to treatment failure. In order to remedy this problem, Professor of the Department of Chemistry Borhane Annabi, holder of the Chair in Cancer Prevention and Treatment , in partnership with the biopharmaceutical company Theratechnologies, is developing an innovative therapeutic approach aimed at mitigating the side effects linked to chemotherapy. and to validate the safety of this targeted therapy for the treatment of colorectal cancer.
This $7.9 million project, supported by Theratechnologies and Mitacs, involves developing a unique anticancer peptide-drug conjugate platform that exploits the internalization functions of SORT1, a biomarker expressed in cancer cells. colorectal. The project is among three promising innovations in the fight against cancer, supported by the CQDM . This non-profit biopharmaceutical research consortium's mission is to support and facilitate collaborative research and development with the aim of transforming innovative technologies into solutions addressing unmet medical needs, while generating significant benefits for the economy. Quebec and Canadian.
“It is with great humility that our research team within the Chair in Cancer Prevention and Treatment welcomes this recognition,” emphasizes Borhane Annabi. CQDM has been incredibly supportive since the beginning of our project to develop a drug against colorectal cancer, without forgetting the unwavering support of our biopharmaceutical partner Theratechnologies. While Quebec now offers colorectal cancer screening to the population, the tangents that any initiative will take in the development of personalized treatment become significant in our fight against this cancer in Quebec.
It was on February 4, World Cancer Day, that the CQDM announced the funding of research and development projects carried out by three Quebec teams, funding made possible thanks to a grant of more than $2.4 million from the Government of Quebec.
You can discover the three collaborative research projects, with a total value of more than $12 million, by visiting the CQDM website .
 
<< Previous
Bullboard Posts
Next >>